Sector News

GSK starts $175M plant to boost production of vaccine star Bexsero

March 22, 2017
Life sciences

Vaccines have been one of the financial bright spots for GlaxoSmithKline and Bexsero, which it picked up in its asset swap with Novartis, has had stellar sales. To boost both, GSK is building a $175 million plant in Germany so it can expand production of the meningococcal B shot.

The antigen production plant is being built in Marsburg, one of the sites GSK acquired when it traded some of its cancer operations to Novartis in exchange for most of the Swiss company’s vaccine operations. The company expects to start validation runs in the third quarter of 2020.

“With the construction of the meningococcal B plant, we are pleased to be moving production for three of the four active components of the meningococcal B vaccine to Marburg soon,” Jochen Reutter, manager of the 780,000 square-foot site, said in a statement.

To make room for the Bexsero expansion, GSK is transferring production of its diphtheria toxoid and tetanus toxoid from Marburg to its vaccine operation in Gödöllő, Hungary. It is adding a $61.5 million facility there to accommodate that work.

There were skeptics when GSK CEO Andrew Witty decided to trade off some older cancer drugs and concentrate on lower margin areas like vaccines and consumer products, but GSK has had success building on vaccines. The U.K. drugmaker recently reported that vax sales were up 14% in 2016 to about $5.73 billion, significantly outpacing growth in much larger pharma and consumer operations.

Bexsero has done particularly well, more than doubling sales in one year to about $486 million for 2016. In fact, GSK got caught off guard by its success last year, running into shortages for awhile.

A month after it got the vaccines from Novartis, it was able to end a yearlong pricing standoff Novartis had with the United Kingdom’s National Health Service to get it added to the country’s national immunization schedule for about 800,000 babies. But when parents of thousands of children missed the NHS program and showed up at private clinics to get their children vaccinated, shortages developed. GSK responded to the “unexpected global demand” and within a couple of months had boosted production of the shot.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend